Feasibility of stroke thrombolysis at Pau Hospital, France;Faisabilité et sécurité de la thrombolyse des accidents vasculaires cérébraux du Centre hospitalier de Pau

Presse Medicale

Volumn 36, Issue 6 I, 2007, Pages 859-866

  Barroso, Bruno ^a   Larrieu, Jean Marc ^a   Morisset, Christophe ^b   Carlier, Philippe ^c   Bersani, Daniel ^d   Dakar, Alexandre ^a   Lagabrielle, Jean François ^e   Larribau, Edouard ^a   Lippa, Alain ^d   Mangon, Hervé ^b   Montaut, Nicole ^e   Rouanet, François ^f  

^a Service de neurologie   (France)

^b Clinique Samu Smur   (France)

^c Service de médecine physique

^d Services de radiologie

^e HÔPITAL DU BOCAGE   (France)

^f HÔPITAL PELLEGRIN   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ALTEPLASE; FIBRINOLYTIC AGENT; RECOMBINANT PROTEIN; TISSUE PLASMINOGEN ACTIVATOR;

ADULT; AGED; ARTICLE; BARTHEL INDEX; BLOOD CLOT LYSIS; BRAIN INFARCTION; CLINICAL ARTICLE; DEATH; DEMOGRAPHY; DRUG SAFETY; EMERGENCY CARE; EMERGENCY WARD; FEASIBILITY STUDY; FEMALE; FOLLOW UP; FRANCE; GENERAL HOSPITAL; HOSPITAL ADMISSION; HUMAN; MALE; MORTALITY; NATIONAL INSTITUTES OF HEALTH STROKE SCALE; OUTCOME ASSESSMENT; PATIENT TRANSPORT; PRACTICE GUIDELINE; PROGNOSIS; RANKIN SCALE; SEX RATIO; STROKE; SYMPTOM; CEREBROVASCULAR ACCIDENT; DRUG ADMINISTRATION; MIDDLE AGED; PATIENT SELECTION; RETROSPECTIVE STUDY; TREATMENT OUTCOME;

ADULT; AGED; CEREBROVASCULAR ACCIDENT; DRUG ADMINISTRATION SCHEDULE; FEMALE; FIBRINOLYTIC AGENTS; FRANCE; HUMANS; MALE; MIDDLE AGED; PATIENT SELECTION; RECOMBINANT PROTEINS; RETROSPECTIVE STUDIES; TISSUE PLASMINOGEN ACTIVATOR; TREATMENT OUTCOME;

EID: 34249658498     PISSN: 07554982     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lpm.2006.10.027     Document Type: Article

References (28)

1. Société Française Neuro-Vasculaire. Recommandations pour la création d'Unités Neuro-Vasculaires. Rev Neurol 157 (2001) 1447-1456
2. Giroud M., and Chatel M. La prise en charge des accidents vasculaires cérébraux en France. Un nouvel enjeu pour la Neurologie dans l'organisation des soins hospitaliers. Rev Neurol 161 (2005) 734-737
3. Adams Jr. H.P., Adams R.J., Brott T., del Zoppo G.J., Furlan A., Goldstein L.B., et al. Stroke Council of the American Stroke Association. Guidelines for the early management of patients with ischaemic stroke. Stroke 34 (2003) 1056-1083
4. European Stroke Initiative Executive Committee and Writing Committee. The European Stroke Initiative recommendations for stroke management: update 2003. Cerebrovasc Dis 16 (2003) 311-318
5. Reed S.D., Cramer S.C., Blough D.K., Meyer K., and Jarvik J.G. Treatment with tissue plasminogen activator and inpatient mortality rates for patients with ischemic stroke treated in community hospitals. Stroke 32 (2001) 1832-1840
6. Wang D.Z., Rose J.A., Honings D.S., Garwacki D.J., Milbrandt J.C., and for the OSF Stroke Team. Treating acute stroke patients with intravenous tPA. The OSF stroke network experience. Stroke 31 (2000) 77-81
7. Wardlaw J.M., Sandercock P.A.G., and Berge E. Thrombolytic therapy with recombinant tissue plasminogen activator for acute ischaemic stroke: where do we go from here? A cumulative meta-analysis. Stroke 34 (2003) 1437-1442
8. Demaerschalk B.M., and Yip T.R. Economic benefit of increasing utilization of intravenous tissue plasminogen activator for acute ischemic stroke in the United States. Stroke 36 (2005) 2500-2503
9. National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. N Engl J Med 333 (1995) 1581-1587
10. Lyden P., Brott T., Tilley B., Welch K.M.A., Mascha E.J., Levine S., et al., for the NINDS TPA Stroke Study Group. Improved reliability of the NIH Stroke Scale using video training. Stroke 31 (1994) 2220-2226
11. Brown D.L., Johnston K.C., Wagner D.P., and Haley E.C. Predicting major neurological improvement with intravenous recombinant tissue plasminogen activator treatment of stroke. Stroke 35 (2004) 147-150
12. Saposnik G., Young B., Silver B., Di Legge S., Webster F., Beletsky V., et al. Lack of improvement in patients with acute stroke after treatment with thrombolytic therapy. JAMA 292 (2004) 1839-1844
13. Van Swieten J.C., Koudstaal P.J., Visser M.C., Schouten H.J.A., and van Gijn J. Interobserver agreement for the assessment of handicap in stroke patients. Stroke 19 (1988) 604-607
14. Mahoney F.I., and Barthel D.W. Functional evaluation: the Barthel index. Md Med J 14 (1965) 61-65
15. Rothwell P.M., Eliasziw M., Gutnikov S.A., Fox A.J., Taylor D.W., Mayberg M.R., et al. Carotid Endarterectomy Trialists' Collaboration. Analysis of pooled data from the randomised controlled trials of endarterectomy for symptomatic carotid stenosis. Lancet 361 (2003) 107-116
16. Heuschmann P.U., Berger K., Misselwitz B., Hermanek P., Leffmann C., Adelmann M., et al., for the German Stroke Registers Study Group and for the Competence Net Stroke. Frequency of thrombolytic therapy in patients with acute ischemic stroke and the risk of in-hospital mortality. The German Stroke Registers Study Group. Stroke 34 (2003) 1106-1113
17. Morisset C., Larrieu J.M., Barroso B., Bersani D., Carlier P., Dakar A., et al. Evaluation d'une filière neuro-vasculaire dans la prise en charge des AVC au Centre Hospitalier de Pau. A propos de 25 cas d'AVC fibrinolysés sur 1 an au CH de Pau. 10e Journées de la Société Française Neuro-Vasculaire (2005), UIC, Paris (p. 13)
18. Qureshi A.I., Kirmani J.F., Sayed M.A., Safdar A., Ahmed S., Ferguson R., et al., Buffalo Metropolitan Area and Erie County Stroke Study Group. Time to hospital arrival, use of thrombolytics, and in-hospital outcomes in ischemic stroke. Neurology 64 (2005) 2115-2120
19. Walters M.R., Muir K.W., Harbison J., Lees K.R., and Ford G.A. Intravenous thrombolysis for acute ischaemic stroke: preliminary experience with recombinant tissue plasminogen activator in the UK. Cerebrovasc Dis 20 (2005) 438-442
20. Hemphill III J.C., and Lyden P. Stroke thrombolysis in the elderly. Risk or benefit?. Neurology 65 (2005) 1690-1691
21. Larrue V., von Kummer R., Müller A., and Bluhmki E. Risk factors for severe hemorrhagic transformation in ischemic stroke patients treated with recombinant tissue plasminogen activator. Stroke 32 (2001) 438-441
22. Bateman B.T., Schumacher C., Boden-Albala B., Berman M.F., Mohr J.P., Sacco R.L., et al. Factors associated with in-hospital mortality after administration of thrombolysis in acute ischemic stroke patients. An analysis of the nationwide inpatient sample 1999 to 2002. Stroke 37 (2006) 440-446
23. Saposnik G., Di Legge S., Webster F., and Hachinski V. Predictors of major neurologic improvement after thrombolysis in acute stroke. Neurology 65 (2005) 1169-1174
24. Thomassen L., Waje-Andreassen U., Naess H., Elvik M.K., and Russel D. Long-term effect of intravenous thrombolytic therapy in acute stroke: responder analysis versus uniform analysis of excellent outcome. Cerebrovasc Dis 20 (2005) 470-474
25. Kwiatkowski T.G., Libmann R.B., Frankel M., Tilley B.C., Morgenstern L.B., Lu M., et al., for the National Institute of Neurological Disorders and Stroke Recombinant Tissue Plasminogen Activator Stroke Study Group. Effects of tissue plasminogen activator for acute ischemic stroke at one year. N Engl J Med 340 (1999) 1781-1787
26. Schmülling S., Grond M., Rudolf J., and Heiss W.D. One-year follow-up in acute stroke patients treated with rtPA in clinical routine. Stroke 31 (2000) 1552-1554
27. Koennecke H.C., Nohr R., Leistner S., and Marx P. Intravenous tPA for ischemic stroke team performance over time, safety, and efficacy in a single-center, 2-year experience. Stroke 32 (2001) 1074-1078
28. Stroke Unit Trialists' Collaboration. Organised inpatient (Stroke Unit) care for stroke. The Cochrane Library, Issue 2 (2003), Update Software, Oxford